Bleeding disorder of unknown cause & amp; unclassified bleeding disorders at US hemophilia treatment centers
Res Pract Thromb Haemost. 2023 Dec 9;8(1):102296. doi: 10.1016/j.rpth.2023.102296. eCollection 2024 Jan.NO ABSTRACTPMID:38292351 | PMC:PMC10824970 | DOI:10.1016/j.rpth.2023.102296 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - January 31, 2024 Category: Hematology Authors: Callie Berkowitz Kristi Kirkland Alice Ma Nigel S Key Source Type: research
Association of laboratory test results with the bleeding history in patients with inherited platelet function disorders (the Bleeding Assesment Tool - LABoratory tests substudy): communication from the Platelet Physiology ISTH-SSC
CONCLUSION: This study shows that altered platelet laboratory assay results are associated with an abnormal ISTH-BAT BS in IPFD.PMID:38292347 | PMC:PMC10825541 | DOI:10.1016/j.rpth.2023.102305 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - January 31, 2024 Category: Hematology Authors: Paolo Gresele Emanuela Falcinelli Loredana Bury Marie-Christine Alessi Giuseppe Guglielmini C éline Falaise Gianmarco Podda Mathieu Fiore Francesco Mazziotta Teresa Sevivas Nuria Bermejo Erica De Candia Meera Chitlur Michele P Lambert Luca Barcella Ana C Source Type: research
Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks
CONCLUSION: In HAVEN 1 to 4, emicizumab demonstrated sustained PKs and PDs and improved coagulation parameters without affecting safety biomarkers.PMID:38282901 | PMC:PMC10818085 | DOI:10.1016/j.rpth.2023.102306 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - January 29, 2024 Category: Hematology Authors: Anna Kiialainen Joanne I Adamkewicz Claire Petry Johannes Oldenburg Steven W Pipe Guy Young Johnny Mahlangu Michaela Lehle Markus Niggli Giancarlo Castaman V íctor Jiménez-Yuste Midori Shima Claude N égrier Christophe Schmitt Source Type: research
Hemophilia Healing with AAV: Navigating the Frontier of Gene Therapy
Curr Gene Ther. 2024 Jan 26. doi: 10.2174/0115665232279893231228065540. Online ahead of print.ABSTRACTGene therapy for hemophilia has advanced tremendously after thirty years of continual study and development. Advancements in medical science have facilitated attaining normal levels of Factor VIII (FVIII) or Factor IX (FIX) in individuals with haemophilia, thereby offering the potential for their complete recovery. Despite the notable advancements in various countries, there is significant scope for further enhancement in haemophilia gene therapy. Adeno-associated virus (AAV) currently serves as the primary vehicle for gen...
Source: Current Gene Therapy - January 29, 2024 Category: Genetics & Stem Cells Authors: Safir Ullah Khan Munir Ullah Khan Muhammad Suleman Amrah Inam Muhammad Azhar Ud Din Source Type: research
Mild haemophilia may add an extra year or two to someone's life
UK figures suggest that when the condition is well treated, it can reduce people ’s risk of heart disease and strokes (Source: New Scientist - Health)
Source: New Scientist - Health - January 19, 2024 Category: Consumer Health News Source Type: research
Postpartum-acquired hemophilia A: case report
We present the case of a 34-year-old female patient with back pain, hematuria and a right gluteal hematoma, with no previous history of bleeding. She was transferred to the emergency department due to the extension of the hemorrhagic manifestations. Diagnosis was confirmed with the coagulation profile, mixing test and the assessment of factor VIII inhibitor tier. The case highlights the importance of considering this condition in a postpartum patient with persistent postoperative bleeding, extensive hematoma and no history of previous bleeding.PMID:38232272 | DOI:10.17843/rpmesp.2023.402.12593 (Source: Revista Peruana de M...
Source: Revista Peruana de Medicina de Experimental y Salud Publica - January 17, 2024 Category: International Medicine & Public Health Authors: Carlos H Contreras-Pizarro Gloria Chumpitaz-Anchiraico Rosario Ticona Sanj ínez Carlos Pe ña-Diaz Source Type: research
